Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: The OMERACT 9 v2 criteria Conference Paper uri icon

Overview

MeSH Major

  • Arthritis
  • Biomarkers
  • Joints

abstract

  • A revised set of validation criteria has been drafted by consensus at OMERACT 9 that focuses on the performance characteristics of biomarker assays, the importance of addressing potential confounders, and the essential requirement for clinical validation studies.

publication date

  • August 2009

Research

keywords

  • Conference Paper

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.3899/jrheum.090346

PubMed ID

  • 19671813

Additional Document Info

start page

  • 1785

end page

  • 91

volume

  • 36

number

  • 8